DOP2012000257A - Derivados del acido 1-amino-2-ciclopropiletilboronico - Google Patents

Derivados del acido 1-amino-2-ciclopropiletilboronico

Info

Publication number
DOP2012000257A
DOP2012000257A DO2012000257A DO2012000257A DOP2012000257A DO P2012000257 A DOP2012000257 A DO P2012000257A DO 2012000257 A DO2012000257 A DO 2012000257A DO 2012000257 A DO2012000257 A DO 2012000257A DO P2012000257 A DOP2012000257 A DO P2012000257A
Authority
DO
Dominican Republic
Prior art keywords
ciclopropiletilboronico
derivatives
amino
acid
compounds
Prior art date
Application number
DO2012000257A
Other languages
English (en)
Inventor
Jing Li
Paul E Fleming
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2012000257(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of DOP2012000257A publication Critical patent/DOP2012000257A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA NUEVOS COMPUESTOS ÚTILES COMO INHIBIDORES DE PROTEASOMA. LA INVENCIÓN TAMBIÉN PROPORCIONA COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS DE LA INVENCIÓN Y MÉTODOS PARA USAR LAS COMPOSICIONES EN EL TRATAMIENTO DE DIFERENTES ENFERMEDADES.
DO2012000257A 2010-03-31 2012-09-28 Derivados del acido 1-amino-2-ciclopropiletilboronico DOP2012000257A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31946410P 2010-03-31 2010-03-31

Publications (1)

Publication Number Publication Date
DOP2012000257A true DOP2012000257A (es) 2012-11-15

Family

ID=44710349

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000257A DOP2012000257A (es) 2010-03-31 2012-09-28 Derivados del acido 1-amino-2-ciclopropiletilboronico

Country Status (26)

Country Link
US (3) US8513218B2 (es)
EP (1) EP2552216B1 (es)
JP (1) JP5933523B2 (es)
KR (1) KR20130036228A (es)
CN (3) CN107266485A (es)
AR (1) AR080863A1 (es)
AU (1) AU2011235227B2 (es)
CA (1) CA2794334C (es)
CL (1) CL2012002733A1 (es)
CO (1) CO6630162A2 (es)
CR (1) CR20120529A (es)
DO (1) DOP2012000257A (es)
EA (1) EA029521B1 (es)
EC (1) ECSP12012249A (es)
MA (1) MA34169B1 (es)
MX (1) MX2012011298A (es)
NZ (1) NZ602622A (es)
PE (1) PE20130383A1 (es)
PH (1) PH12012501943A1 (es)
RU (1) RU2012146101A (es)
SG (1) SG184222A1 (es)
TN (1) TN2012000465A1 (es)
UA (1) UA110612C2 (es)
UY (1) UY33314A (es)
WO (1) WO2011123502A1 (es)
ZA (2) ZA201207406B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5436860B2 (ja) 2005-11-09 2014-03-05 オニキス セラピューティクス， インク． 酵素阻害のための化合物
NZ573759A (en) 2006-06-19 2012-03-30 Proteolix Inc Peptide epoxyketones for proteasome inhibition
EA018973B1 (ru) 2007-10-04 2013-12-30 Оникс Терапьютикс, Инк. Кристаллические пептидные кето-эпоксидные ингибиторы протеаз и синтез кето-эпоксидов аминокислот
HRP20150592T4 (hr) 2008-06-17 2025-02-14 Millennium Pharmaceuticals, Inc Organoborni esterski spojevi i njihove farmaceutske kompozicije
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
BRPI0919668A2 (pt) 2008-10-21 2018-05-29 Onyx Therapeutics, Inc. terapia de combinação com epóxi-cetonas de peptídeo
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP2498793B1 (en) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib for use in metastasis suppression
PH12012501719A1 (en) 2010-03-01 2012-11-12 Onyx Therapeutics Inc Compounds for immunoproteasome inhibition
JP5933523B2 (ja) 2010-03-31 2016-06-08 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． １−アミノ−２−シクロプロピルエチルボロン酸の誘導体
PL3412676T3 (pl) 2010-08-10 2021-04-06 Melinta Therapeutics, Inc. Cykliczne pochodne estrowe kwasu boronowego, sposób otrzymywania oraz ich zastosowania terapeutyczne
CA2855368A1 (en) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
CA2855356A1 (en) 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
US9688702B2 (en) * 2011-12-22 2017-06-27 Ares Trading Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
CA2862492A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
CN103570806B (zh) * 2012-07-26 2020-04-07 圣特莱国际公司 多肽环氧酮化合物
EP2941246A4 (en) 2013-01-04 2016-12-21 Rempex Pharmaceuticals Inc BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2925935A1 (en) 2013-10-03 2015-04-09 Millennium Pharmaceuticals, Inc. Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis
WO2015106200A2 (en) 2014-01-10 2015-07-16 Cornell University Dipeptides as inhibitors of human immunoproteasomes
EP3140310B1 (en) 2014-05-05 2019-08-07 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
US9687497B1 (en) 2014-05-05 2017-06-27 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
SG10202003693RA (en) 2014-05-20 2020-05-28 Millennium Pharm Inc Boron-containing proteasome inhibitors for use after primary cancer therapy
US10206937B2 (en) 2014-07-01 2019-02-19 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
EP4180041A1 (en) 2014-08-07 2023-05-17 Mayo Foundation for Medical Education and Research Compounds and methods for treating cancer
US11202817B2 (en) 2014-08-18 2021-12-21 Cornell University Dipeptidomimetics as inhibitors of human immunoproteasomes
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3362754B1 (en) 2015-10-15 2021-12-22 Cornell University Proteasome inhibitors and uses thereof
MY196909A (en) 2016-06-30 2023-05-09 Qpex Biopharma Inc Boronic acid derivatives and therapeutic uses thereof
EP3589659B1 (en) 2017-02-28 2025-04-09 Mayo Foundation for Medical Education and Research Combinations for use in the treatment of cancer
EP3694864B1 (en) 2017-10-11 2025-03-05 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
US11203613B2 (en) 2017-10-11 2021-12-21 Cornell University Peptidomimetic proteasome inhibitors
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
AU2019256351B2 (en) 2018-04-20 2024-02-29 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
US12552815B2 (en) 2020-05-05 2026-02-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203706A (en) 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US5159060A (en) 1988-05-27 1992-10-27 Mayo Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
EP0583536B1 (en) 1992-08-14 1997-03-05 The Procter & Gamble Company Liquid detergents containing an alpha-amino boronic acid
US5492900A (en) 1993-09-10 1996-02-20 Neutron Technology Corporation Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA)
US6060462A (en) 1993-10-20 2000-05-09 Dupont Pharmaceuticals Company Electrophilic peptide analogs as inhibitors of trypsin-like enzymes
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
ATE240113T1 (de) 1997-02-15 2003-05-15 Millennium Pharm Inc Behandlung von infarkten durch inhibierung von nf-kappab
EP1017398A1 (en) 1997-09-25 2000-07-12 Proscript, Inc. Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases
JP2002508321A (ja) 1997-12-16 2002-03-19 セフアロン・インコーポレーテツド 抗腫瘍薬としての使用のための多触媒性プロテアーゼ阻害剤
US6169076B1 (en) 1999-03-31 2001-01-02 Glcosyn Pharmaceuticals, Inc. P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols
WO2001002601A2 (en) 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
US7122627B2 (en) * 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
EE05442B1 (et) 2000-02-29 2011-08-15 Bristol-Myers Squibb Company V„ikeses annuses entekaviiri sisaldav ravimkoostis B-hepatiidi viirusinfektsiooni raviks ning meetod selle valmistamiseks
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
PT3078667T (pt) 2001-01-25 2018-12-28 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulação de compostos de ácido borónico
JPWO2003033507A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
JP4412586B2 (ja) 2002-01-08 2010-02-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 エポネマイシンおよびエポキソマイシン類似物およびそれらの用途
US20060084592A1 (en) 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
TW200418791A (en) * 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
UA88771C2 (ru) * 2003-08-14 2009-11-25 Сефалон, Инк. Ингибиторы протеасомы и способ их применения (варианты)
RS53259B (sr) 2004-03-30 2014-08-29 Millennium Pharmaceuticals Inc. Sinteza bortezomiba
KR20080030079A (ko) 2005-07-05 2008-04-03 트러스티즈 오브 터프츠 칼리지 섬유아세포 활성 단백질 알파의 억제제
JP2009524681A (ja) 2006-01-27 2009-07-02 フェノミックス コーポレーション Ｃ型肝炎ウイルスセリンプロテアーゼインヒビターおよびそのための使用
WO2009006473A2 (en) 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
EP2178888B1 (en) 2007-08-06 2012-07-04 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
HRP20150592T4 (hr) 2008-06-17 2025-02-14 Millennium Pharmaceuticals, Inc Organoborni esterski spojevi i njihove farmaceutske kompozicije
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
JP5933523B2 (ja) 2010-03-31 2016-06-08 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． １−アミノ−２−シクロプロピルエチルボロン酸の誘導体

Also Published As

Publication number Publication date
KR20130036228A (ko) 2013-04-11
CR20120529A (es) 2013-01-11
ZA201207406B (en) 2014-01-29
EA029521B1 (ru) 2018-04-30
CO6630162A2 (es) 2013-03-01
CA2794334C (en) 2018-06-12
PE20130383A1 (es) 2013-04-24
NZ602622A (en) 2015-01-30
US20140011998A1 (en) 2014-01-09
SG184222A1 (en) 2012-10-30
CN102892291A (zh) 2013-01-23
CA2794334A1 (en) 2011-10-06
US20110245203A1 (en) 2011-10-06
EA201290980A1 (ru) 2013-03-29
EP2552216B1 (en) 2018-01-24
AU2011235227A1 (en) 2012-10-18
AU2011235227B2 (en) 2016-09-08
EP2552216A1 (en) 2013-02-06
US20140179631A1 (en) 2014-06-26
US8513218B2 (en) 2013-08-20
TN2012000465A1 (en) 2014-01-30
JP2013523760A (ja) 2013-06-17
CL2012002733A1 (es) 2013-01-25
ZA201308086B (en) 2015-03-25
CN107266485A (zh) 2017-10-20
UY33314A (es) 2011-10-31
RU2012146101A (ru) 2014-05-10
ECSP12012249A (es) 2012-11-30
JP5933523B2 (ja) 2016-06-08
MA34169B1 (fr) 2013-04-03
CN106008570A (zh) 2016-10-12
PH12012501943A1 (en) 2017-08-23
EP2552216A4 (en) 2013-07-31
WO2011123502A1 (en) 2011-10-06
US8703743B2 (en) 2014-04-22
AR080863A1 (es) 2012-05-16
MX2012011298A (es) 2012-11-06
UA110612C2 (uk) 2016-01-25
US9023832B2 (en) 2015-05-05

Similar Documents

Publication Publication Date Title
CR20120529A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CR20150610A (es) Compuestos de pirimidino sustituido y derivados para combatir plagas de animales
ECSP11011011A (es) Derivados de acido 1-amino-2-ciclobutiletilborónico
PE20151023A1 (es) Triazolopirazinas
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
PE20151067A1 (es) Inhibidores de autotaxina
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
NI201400089A (es) COMPUESTOS DE OXAZOLIDIN - 2 - ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
UY32809A (es) Compuestos y composiciones como inhibidores de cinasa s y k
UY35827A (es) Derivados de triazolopirazina como inhibidores de la proteína brd4
UY35395A (es) Inhibidores de bromodominios tetracíclicos
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
NI201200029A (es) Compuestos y composiciones como inhibidores de cinasa de proteína
NI201100166A (es) Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
CR20140573A (es) Inhibidores del nampt
CR20150248A (es) Derivados de oxazolidin-2-ona-pirimidina
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
DOP2014000046A (es) COMPOSICIONES Y MÉTODOS PARA TRATAR EL CÁNCER USANDO EL INHIBIDOR DE PI3Kbeta Y EL INHIBIDOR DE LA VÍA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF
PE20150674A1 (es) Azaheterociclos como inhibidores de bir2 y/o bir3